OncoMatch/Clinical Trials/NCT05009927
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Is NCT05009927 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Imatinib tablets for metastatic gastrointestinal stromal tumor (gist).
Treatment: Imatinib tablets — This is a 2 arms study concerning patients under imatinib treatment for at least 10 years of treatment with locally advanced/metastatic GIST. In the first arm, patients will discontinue Imatinib treatment. This arm will allow to determine if the re-introduction of Imatinib at relapse is still an efficient treatment for the control of disease. In the second arm, patients will continue Imatinib treatment, allowing to determine if the continuation of this treatment is efficient for disease control, by the rate of non-progression disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastrointestinal Stromal Tumor
Biomarker criteria
Required: KIT expression (immunohistochemical documentation of c-kit (CD117) expression)
immunohistochemical documentation of c-kit (CD117) expression either by the primary tumor or metastases
Excluded: PDGFRA D842V
Patient with GIST harboring the mutation D842V in PDGFRA
Disease stage
Required: Stage IV
Metastatic disease required
malignant advanced/metastatic GIST
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: imatinib (imatinib)
Patient must be under imatinib treatment (at 300 or 400mg/day) maintained for 10 years or over with no more than 12 months in total or 3 consecutive months of interruption during the treatment period
Cannot have received: other approved or investigational antineoplastic agents
Patient concurrently using other approved or investigational antineoplastic agents
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify